Inotiv
CLOSE ×
Inotiv

Now Available!

2025 North American Product Guide

Receive a copy of our current research models and services product guide.

Download Now

Neuroscience

Revolutionize Drug Discovery with Inotiv’s Comprehensive Neuroscience Program

Discover Our Therapeutic Areas

Quantify any protein, in any sample, with any modification, without antibodies

Target Sufficiency® enables direct, quantitative analysis of drug target systems in cells, biofluids, tissues, and tissue models, including formalin-fixed, paraffin-embedded (FFPE) tissues.

Learn More

Supporting your critical research with our inflation reduction model program

Reduce costs with our complimentary sample for evaluation in your lab.

Claim Your Offer

In vivo solutions for Developmental and Reproductive Toxicology and Juvenile Animal Studies

Learn More

Count on our expertise in IBD animal models for your next in vivo study

Discover More

Discover our array of highly characterized PDX models

Discover More

Enhanced navigational menu. New domain. Improved experience.

Search by therapeutic area, research phase, and products and services at inotiv.com.

Learn More

Expect More From Your Discovery, Development and Research Models Partner

icon-toxicology General Toxicology General Toxicology Inotiv offers a range of general toxicology studies to evaluate the safety of drugs, medical devices, and other chemicals. We design and conduct studies according to international regulations and our toxicology expertise can help assess potential risks and ensure the safety of your product. icon-histology Histology Histology Our industry-leading histology laboratories support your discovery and nonclinical development projects with a wide range of services. From tissue processing to digital analysis, our team delivers the quality you expect.   icon-histology-pathology Pathology Pathology Access our world-class anatomical, clinical, and medical device pathology team that provides services from histochemistry to digital pathology including IHC, IF, and ISH to stereology, and more.  icon-drug-metabolism-bioanalysis-pk DMPK DMPK From hit-to-lead to lead optimization through candidate selection, our in vitro, in vivo, and bioanalytical teams offer the fit-for-purpose solutions you need at any stage of development to help you analyze, answer, and advance.  icon-consulting Consulting Consulting Our experts deliver the insights you deserve to get the answers you need, whether in DMPK data analysis, biomarker analysis, or bioequivalence studies. research-models Research Models Research Models Paired with the most comprehensive range of research models in the industry, we offer the experience, animal welfare, quality, and consistency that is essential to your success. icon-model-services Research Model Services Research Model Services Our research model services group provides high-quality support services worldwide, including genetically engineered models and services (GEMS), contract breeding services, surgical services, and more. icon-teklad Teklad Diet and Bedding Teklad Diet and Bedding What comes out of your research depends in large part on what goes into your research models. Ensuring models have the most appropriate laboratory animal diet, bedding, and enrichment is critical to maintaining consistent, reliable data.

Explore Our Full Offering of Services and Products

inotiv-lab-technicians-1

Discovery and Development 

Inotiv delivers a broad array of nonclinical and analytical services from discovery through clinical development.  

hp-hero-request-a-sample

Research Models and Services 

Inotiv provides the broadest range of research models and related services to pharmaceutical and biotech companies, government, academia, and other life science organizations.  

The Latest From Inotiv

Inotiv Ranked Number 138 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

November 21, 2024 Acquiring and Developing Services and Resources to Build a Full Service, Customer-Focused CRO has Fueled 847% Revenue Growth ...

Inotiv, Inc. to Report Fiscal 2024 Fourth Quarter and Full Year Results and Host Conference Call on Tuesday, December 3, 2024

November 20, 2024 WEST LAFAYETTE, Ind., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”),&...

Inotiv Awarded $1.8M Grant for Development of Novel Chronic Kidney Disease (CKD) Research Model

November 14, 2024 Inotiv is incredibly pleased to announce that we’ve received a $1.8 million dollar grant to develop a novel chronic kidney disease (CKD) in vivo model that can bridge the...

On-demand Webinar

Not All IBD Models Are Created Equally

How Differences Between Experimental IBD Models Can Impact Your Drug Development Program

Scientific Poster

Comparative Evaluation of Different Plating Methodologies and Sources of Induced S9 Metabolic Activation on the Mutagenic Potential of N-Nitrosodipropylamine Using the Ames Test

Due to the current FDA concern and guidance on reducing the risk of Nitrosamine impurities in human drugs, there has been an increased industry need for testing of these impurities using the Bacterial Reverse Mutation (Ames) test. As Nitrosamines are not readily detectable by standard Ames methodologies, specifically cited in the Ames testing guideline (OECD 471), the need for a robust protocol better suited for this class of compounds is warranted.

Subscribe to updates from Inotiv

Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.

Subscribe now